Engineering of affibody molecules for therapy and diagnostics

Area of Science:

• Biotechnology
• Molecular Biology
• Protein Engineering

Background:

• Affibody molecules are small, non-immunoglobulin affinity ligands derived from a Z-domain scaffold.
• They exhibit unique characteristics, including lack of sequence/structural homology to antibodies and versatile production methods (peptide synthesis, recombinant expression).
• Their small size and robustness make them suitable for various biological applications.

Purpose of the Study:

• To describe general strategies for optimizing Affibody molecules.
• To tailor Affibody molecules for specific applications in diagnostic imaging and therapy.
• To highlight the differences in optimization requirements for imaging versus therapeutic uses.

Main Methods:

• Selection of Affibody molecules from combinatorial libraries based on the Z-domain scaffold.
• Protein engineering techniques to adapt Affibody molecules for targeted applications.
• Comparative analysis of optimization strategies for diagnostic imaging and therapeutic modalities.

Main Results:

• Affibody molecules can be engineered to bind a wide range of protein targets.
• Optimization strategies differ significantly between molecular imaging and therapeutic applications.
• The Z-domain scaffold provides a robust platform for developing targeted protein binders.

Conclusions:

• Affibody molecules are highly adaptable affinity ligands with broad application potential.
• Strategic protein engineering is crucial for maximizing Affibody molecule efficacy in diagnostics and therapeutics.
• The development of application-specific Affibody molecules represents a significant advancement in molecular medicine.